字号·· | 护眼
彭博社

中国AI生物技术公司获阿曼支持融资2亿美元China AI Biotech Firm Raises $200 Million in Oman-Backed Round

点「原文对照」整页切到原文,或双击某段只看那段的原文。

上海SEMICON China展会现场,Megarobo Technologies Co.展位上的标识。Signage at the Megarobo Technologies Co. booth at the Semicon China expo in Shanghai.

中国生物技术初创企业 MegaRobo Technologies(以下简称“MegaRobo”)已从包括阿曼主权财富基金在内的投资者处筹集近 2 亿美元资金,投资者正涌入利用人工智能和机器人技术加速药物研发的公司。

Published: 2026-11-19T08:20:00+08:00 Chinese biotech upstart MegaRobo Technologies has raised nearly $200 million from investors including Oman’s sovereign wealth fund, as investors pile into companies using artificial intelligence and robotics to accelerate drug research.

MegaRobo 在周四的一份声明中表示,阿曼投资局参与了本轮融资,招商局国际、现有投资方亚洲投资资本、Granite Asia 以及创新工场也跟投。声明未披露公司估值。募集资金将用于研发和全球扩张。

The Oman Investment Authority participated in the round alongside CMB International and existing backers including Asia Investment Capital, Granite Asia and Sinovation Ventures, MegaRobo said in a statement Thursday, without disclosing its valuation. The proceeds will be used for research and development and global expansion.

投资者正向所谓的“AI for Science”(人工智能驱动科学研究)初创企业注资,这些公司将 AI 模型与自动化实验室相结合,以加快药物发现和材料研究。MegaRobo —— 该公司在 2022 年融资 3 亿美元后成为独角兽 —— 属于新兴群体之一,致力于实现实验自动化并生成支撑上述工作的数据,与国内同行包括在香港上市的智翔金泰控股有限公司、总部位于北京的 DP Technology,以及美国大型企业安捷伦科技公司和 Twist Bioscience Corp. 等展开竞争。

Investors are pouring capital into so-called AI-for-science startups that combine AI models with automated laboratories to speed up drug discovery and materials research. MegaRobo — which became a unicorn after raising $300 million in 2022 — is part of an emerging group seeking to automate the experiments and generate the data that underpin that work, competing with domestic peers including Hong Kong-listed XtalPi Holdings Ltd. and Beijing-based DP Technology and bigger US companies including Agilent Technologies Inc. and Twist Bioscience Corp.

创始人黄楠在采访中表示,MegaRobo 于 2025 年中在香港提交上市申请,公司目前仍“在排队”等待首次公开募股(IPO)。

MegaRobo filed for a listing in Hong Kong in mid-2025 and the company remains “in the queue” for an initial public offering, founder Daniel Huang said in an interview.

黄楠于 2016 年与两名前科学仪器制造商同事共同创立 MegaRobo。公司开发机器人和 AI 系统,实现实验室工作自动化,涵盖药物发现、样本处理和临床检测等环节。

Huang founded MegaRobo in 2016 with two former colleagues from a scientific-instruments maker. The company develops robotics and AI systems that automate laboratory work, including drug discovery, sample processing and clinical testing.

其 1200 多家客户包括制药和生物技术公司以及学术机构。黄楠表示,MegaRobo 约 80% 的收入来自中国,公司在海外看到“大量”潜力,特别是在共建“一带一路”国家。

Its more than 1,200 customers include pharmaceutical and biotech companies and academic institutions. About 80% of MegaRobo’s revenue comes from China, and the company sees a “great deal” of potential abroad, particularly in countries along China’s Belt and Road initiative, Huang said.

基于Transformer架构的大语言模型的兴起,也创造了新的需求来源。黄某表示,寻求大量高质量科学训练数据的AI开发者正成为MegaRobo自动化实验室系统的客户,但他未透露这些客户的身份。

The rise of transformer-based large language models has also created a new source of demand. AI developers seeking large volumes of high-quality scientific training data are becoming customers of MegaRobo’s automated laboratory systems, Huang said, without identifying them.

尽管如此,制药行业长期以来一直希望AI能缩短漫长的药物发现和开发流程,并提高成功率,但该技术尚未将新疗法推向市场。许多AI for Science(人工智能驱动科学研究)公司仍处于亏损状态。

Still, while the drug industry has long hoped AI can shorten the lengthy process of discovering and developing medicines and improve the odds of success, the technology has yet to deliver a new treatment to market. Many AI-for-science companies remain unprofitable.

地缘政治紧张局势构成另一潜在障碍。随着AI成为中美技术竞争日益重要的战场,寻求在美国拓展业务的中国公司面临更严格的审查和限制。

Geopolitical tensions present another potential hurdle. As AI becomes an increasingly important front in the US-China technology rivalry, Chinese companies seeking to expand in the US face heightened scrutiny and restrictions.

黄某表示,MegaRobo的营收保持了约30%的年增长率,利润率有所改善。目前三分之二的销售额来自他所谓的“AI原生产品”——模块化系统,可像乐高积木一样根据客户需求进行组装和修改。

MegaRobo’s revenue has maintained annual growth of about 30%, with margins improving, Huang said. Two-thirds of sales now come from what he described as AI-native products — modular systems that, like Lego building blocks, can be assembled and modified according to customers’ needs.

阅读媒体原文 ↗